In addition, in lung cancer [9], breast cancer [10], hepatocellular carcinoma [11], colon cancer [12], and pancreatic cancer [13], CD133 expression has been reported to be strongly related not only to tumor progression, but also to treatment resistance. The gene discussed is PROM1; the disease is hepatocellular carcinoma.